Is There a New Drug Beyond Floxuridine for Intra-Arterial Hepatic Chemotherapy in Liver Metastases From Colorectal Cancer?

week,andFUDRat0.12mg/kgpumpvolumepumpflow rate in an adjuvant regimen is feasible. With a median follow-up time of 26 months, the 2-year survival rate is 89%. All 27 patients who were treated at MTD are alive. The choice of irinotecan for systemic therapy was used because lung metastases express a higher level of thymydylate synthetase (TS) than in other sites, 2 and fluorouracil or FUDR (inhibitors of TS)maynotbethemostappropriatedrugtousetocontrolthe development of disease in the lung. Instead, these drugs are active in liver metastases in which TS could be lower. This hypothesis is not totally accepted. More reports show that in